1-11 of 11
Manisha H. Shah
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms

Dwight H. Owen, Brooke Benner, Lai Wei, Vineeth Sukrithan, Ashima Goyal, Ye Zhou, Carly Pilcher, Sheryl-Ann Suffren, Gwen Christenson, Nancy Curtis, Megan Jukich, Emily Schwarz, Himanshu Savardekar, Ruthann Norman, Sarah Ferguson, Barbara Kleiber, Robert Wesolowski, William E. Carson, III, Gregory A. Otterson, Claire F. Verschraegen, Manisha H. Shah, Bhavana Konda
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (4): 731–741.
https://doi.org/10.1158/1078-0432.CCR-22-1552
Published: 16 February 2023
View article titled, A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
Open the PDF for A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms in another window
Includes: Supplementary data
Journal Articles

A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors

Sandip P. Patel, Megan Othus, Young Kwang Chae, Francis J. Giles, Donna E. Hansel, Preet Paul Singh, Annette Fontaine, Manisha H. Shah, Anup Kasi, Tareq Al Baghdadi, Marc Matrana, Zoran Gatalica, W. Michael Korn, Jourdain Hayward, Christine McLeod, Helen X. Chen, Elad Sharon, Edward Mayerson, Christopher W. Ryan, Melissa Plets, Charles D. Blanke, Razelle Kurzrock
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (10): 2290–2296.
https://doi.org/10.1158/1078-0432.CCR-19-3356
Published: 15 May 2020
View article titled, A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors
Open the PDF for A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors in another window
Includes: Supplementary data
Journal Articles

A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer

Martin Schlumberger, Barbara Jarzab, Maria E. Cabanillas, Bruce Robinson, Furio Pacini, Douglas W. Ball, Judith McCaffrey, Kate Newbold, Roger Allison, Renato G. Martins, Lisa F. Licitra, Manisha H. Shah, Donald Bodenner, Rossella Elisei, Lynn Burmeister, Yasuhiro Funahashi, Min Ren, James P. O'Brien, Steven I. Sherman
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (1): 44–53.
https://doi.org/10.1158/1078-0432.CCR-15-1127
Published: 03 January 2016
View article titled, A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer
Open the PDF for A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer in another window
Includes: Supplementary data
Journal Articles

Complete Longitudinal Analyses of the Randomized, Placebo-Controlled, Phase III Trial of Sunitinib in Patients with Gastrointestinal Stromal Tumor following Imatinib Failure

George D. Demetri, Christopher R. Garrett, Patrick Schöffski, Manisha H. Shah, Jaap Verweij, Serge Leyvraz, Herbert I. Hurwitz, Antonio Lopez Pousa, Axel Le Cesne, David Goldstein, Luis Paz-Ares, Jean-Yves Blay, Grant A. McArthur, Qiang (Casey) Xu, Xin Huang, Charles S. Harmon, Vanessa Tassell, Darrel P. Cohen, Paolo G. Casali
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (11): 3170–3179.
https://doi.org/10.1158/1078-0432.CCR-11-3005
Published: 31 May 2012
View article titled, Complete Longitudinal Analyses of the Randomized, Placebo-Controlled, Phase III Trial of Sunitinib in Patients with Gastrointestinal Stromal Tumor following Imatinib Failure
Open the PDF for Complete Longitudinal Analyses of the Randomized, Placebo-Controlled, Phase III Trial of Sunitinib in Patients with Gastrointestinal Stromal Tumor following Imatinib Failure in another window
Includes: Supplementary data
Journal Articles

Role of BRAF in Thyroid Oncogenesis

Lisa M. Caronia, John E. Phay, Manisha H. Shah
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (24): 7511–7517.
https://doi.org/10.1158/1078-0432.CCR-11-1155
Published: 18 December 2011
View article titled, Role of BRAF in Thyroid Oncogenesis
Open the PDF for Role of BRAF in Thyroid Oncogenesis in another window
Journal Articles

Targeting RET Receptor Tyrosine Kinase Activation in Cancer

John E. Phay, Manisha H. Shah
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (24): 5936–5941.
https://doi.org/10.1158/1078-0432.CCR-09-0786
Published: 16 December 2010
View article titled, Targeting RET Receptor Tyrosine Kinase Activation in Cancer
Open the PDF for Targeting RET Receptor Tyrosine Kinase Activation in Cancer in another window
Journal Articles

Circulating Levels of Soluble KIT Serve as a Biomarker for Clinical Outcome in Gastrointestinal Stromal Tumor Patients Receiving Sunitinib following Imatinib Failure

Samuel E. DePrimo, Xin Huang, Martin E. Blackstein, Christopher R. Garrett, Charles S. Harmon, Patrick Schöffski, Manisha H. Shah, Jaap Verweij, Charles M. Baum, George D. Demetri
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (18): 5869–5877.
https://doi.org/10.1158/1078-0432.CCR-08-2480
Published: 14 September 2009
View article titled, Circulating Levels of Soluble KIT Serve as a Biomarker for Clinical Outcome in Gastrointestinal Stromal Tumor Patients Receiving Sunitinib following Imatinib Failure
Open the PDF for Circulating Levels of Soluble KIT Serve as a Biomarker for Clinical Outcome in Gastrointestinal Stromal Tumor Patients Receiving Sunitinib following Imatinib Failure in another window
Includes: Supplementary data
Journal Articles

HDAC Inhibitors and Cardiac Safety

Manisha H. Shah, Miguel A. Villalona-Calero, Guido Marcucci, John C. Byrd, Michael R. Grever
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (3): 1068.
https://doi.org/10.1158/1078-0432.CCR-06-2380
Published: 08 February 2007
View article titled, HDAC Inhibitors and Cardiac Safety
Open the PDF for HDAC Inhibitors and Cardiac Safety in another window
Journal Articles

A Phase I Study of Ultra Low Dose Interleukin-2 and Stem Cell Factor in Patients with HIV Infection or HIV and Cancer

Manisha H. Shah, Aharon G. Freud, Don M. Benson, Jr., Amy K. Ferkitich, Bruce J. Dezube, Zale P. Bernstein, Michael A. Caligiuri
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (13): 3993–3996.
https://doi.org/10.1158/1078-0432.CCR-06-0268
Published: 03 July 2006
View article titled, A Phase I Study of Ultra Low Dose Interleukin-2 and Stem Cell Factor in Patients with HIV Infection or HIV and Cancer
Open the PDF for A Phase I Study of Ultra Low Dose Interleukin-2 and Stem Cell Factor in Patients with HIV Infection or HIV and Cancer in another window
Journal Articles

Cardiotoxicity of Histone Deacetylase Inhibitor Depsipeptide in Patients with Metastatic Neuroendocrine Tumors

Manisha H. Shah, Philip Binkley, Kenneth Chan, Jim Xiao, Daria Arbogast, Minden Collamore, Yasser Farra, Donn Young, Michael Grever
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (13): 3997–4003.
https://doi.org/10.1158/1078-0432.CCR-05-2689
Published: 03 July 2006
View article titled, Cardiotoxicity of Histone Deacetylase Inhibitor Depsipeptide in Patients with Metastatic Neuroendocrine Tumors
Open the PDF for Cardiotoxicity of Histone Deacetylase Inhibitor Depsipeptide in Patients with Metastatic Neuroendocrine Tumors in another window
Journal Articles

Phase II Study of the Proteasome Inhibitor Bortezomib (PS-341) in Patients with Metastatic Neuroendocrine Tumors

Manisha H. Shah, Donn Young, Hedy L. Kindler, Iain Webb, Barbara Kleiber, John Wright, Michael Grever
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (18): 6111–6118.
https://doi.org/10.1158/1078-0432.CCR-04-0422
Published: 24 September 2004
View article titled, Phase II Study of the Proteasome Inhibitor Bortezomib (PS-341) in Patients with Metastatic Neuroendocrine Tumors
Open the PDF for Phase II Study of the Proteasome Inhibitor Bortezomib (PS-341) in Patients with Metastatic Neuroendocrine Tumors in another window